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THIF, modern science of enzymology has many ramifications and biological
relationships. Over 700 enzymes appear in current literature, although in this
review only those with involvement in the neoplastic processes of cancer win be
discussed, and much is necessarily omitted with dehberation, with regret, or with
inadvertence. The emphasis herein is placed on relationships of enzymology
to cancer and this, in accordance with significance and exigencies of space.
DiagnosticaRy, enzymology contributes to a limited extent to the chnical
knowledge of cancer by enabhng diagnosis in certain initial stages, by making
early recognition possible while disease is histologicaRy unrecognizable, by locat-
ing with precision the organ site of the malignant growth of tissue, by assisting
in differentialdiagnosis orpathologic process oftumorgrowth, by confirming and
and supplementing cytologic and histologic findings, byreflecting the therapeutic
responsiveness and chnical course of a carcinoma or sarcoma, and by aiding in
prognostication. These relationships seem more exphcit when the enzymes
are considered a mosaic within theproteins ofbody fluids and tissues, the enzyme
activity being a resultant of apoenzymes, coenzymes, activators, inhibitors and
anti-enzymes. Present day applications of enzymology and biochemistry can
be effective in organ differentiation in neoplastic disease ff skflfully utilized ;
for example, five enzymes (acid phosphatase, alkahne phosphatase, lactate
dehydrogenase, aspartate aminotransferase and alanine aminotransferase) as
altered in serum, pleural and pericardial effusions, and cerebrospinal fluid can
specificaRy indicate the site of cancer whether it is carcinoma metastatic to bone,
intrahepaticly homa and carcinoma, metastaticprostaticcarcinoma,pancreatic
carcinomawith obstructivejaundice, carcinomametastatic topleurawitheffusion,
carcinoma metastatic to pericardium with effusion, or intracerebral metastatic
carcinoma.
TherapeuticaRy, enzymology offers a means of treatment in tumors, although
certainlyinsufficientlyinvestigated to date. Paul(I962) statedthat canceralways
involved a local breakdown of the tissue homeostatic mechanisms. If by exo-
genous influence the anabohe or catabohe enzyme processes in various tumor
growth could be understood and corrected, a key would be found to cancer
therapy. No substance, so far, exists which when administered as a chemo-
therapeutic agent to a patient with disseminated cancer, causes the growth to
disappear, and one must conclude that current therapeutics are paluative.
Tnvestigations of carcinochemotherapy have disclosed much on chemothera-
peutic poisons, as nitrogen mustards and polysaccharides ; on hormones, as
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estrogens, androgens, progesterones, cortisones and ACTH ; on mitoses inhibitors
exemplified by colchicine and its relatives ; and, on the antimetabolites, among
them the folic acid and purine antagonists. All such reports involve to some
extent enzyme effect or affect. Normally enzyme activity in the serum seems
minimal compared with that in the tissues, but appreciably increased in the
presence of various organic lesions.
Definitively, enzymology seems nearest to explaining cancer, possiblyresulting
fro'm systematic efforts of anti-cancer chemotherapy and long intense cancer
research. References to cancer in this review are pertaining to the generahzed
disease, embracing carcinoma, leukemia, lymphosarcoma and Hodgkin's disease.
Historically, enzymology hasemerged from the obsolete era ofthe direct study
ofmahgnant cells with thelightmicroscope into a true science. Sorensen in 1909
showed that enzyme activity was dependent upon pH factors ; Michaelis, and
Menten (I913) asserted that the enzyme reaction rate was proportional to the
concentration of an assumed intermediate enzyme substrate complex ; Warburg
in the reports ofWarburg, Posener and Negelein (1924), Warburg (1956) and as
reiterated by Weinhouse (1960) presented his famous concept on the prevalence
of glycolysis and possibly, impaired respiration in certain tumors; Greenstein
(1956) stated in the second famous concept his hypothesis of near uniformity of
enzyme activities in a variety of transplanted tumors; Potter (1956, 1957, 1958)
introduced the third famous concept of cancer metabolism called the
" deletion
hypothesis
" which postulated (Bergel, 1961) that during the development
towards the malignant state and after the cell has lost certain essential con-
stituents, the presence ofwhich, under normal conditions, exerts a vital influence
on the regulation of growth and cell division; and such men as Berenblum
(1956), Bodansky (1956 1958, 1959), Wroblewski (1958b, 1959b) Gutman (1959),
DesnueRe (1961), Bergel (1956, 1960, 1961) and numerous others have heavily
contributed to cancer enzymology. King in 1959 has given an excellent history
of common enzymes and the ideas concerning them in relation to physiologic
processes, pointing out the importance ofenzymes inpathologic processes and the
great usefulness of their determination in body fluids as relates to diagnosis,
prognosis and assessment oftherapy.
This review will be an attempt to survey the field of cancer enzymes; to
assign anorganized classification to the enzymes involved inoncology ; to present
various advances made ; to discuss existing concepts, some methodology and
trends ; to point out lesser known areas of current research ; and, to form a basis
for harnessing the field of tumor enzymology wbich seems increasingly in a state
of flux.
NOMENCLATURE, TERMINOLOGY AND CLASSIFICATION
The field ofenzymologystrictlydefined, concerns thechemistry and mechanism
of enzyme-catalyzed reactions, as weH as the chemistry of the enzymes them-
selves (Colowick and Kaplan, 1955). As biocatalysts, the enzymes carry the
advantage that they can be assayed more easily than other cellular constituents
due to their function and by necessity, through tbis, include substrates and
products of their catalytic activities (Bergel, 1961). Bodansky (1959) called
enzymes protein catalysts and reported in detail on mechanisms that may be
important for diagnostic appheation of enzymes in medicine. He also reported
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the organism ; distribution ofenzymes among the various intracellular structures,
as nucleus, mitochondria, microsomes and the supernatant fraction rich in glyco-
lvtic enzymes remaining after the centrifugation of these particulate structures
and, the localization of certain groups of enzymes indicating the association of
metabolic function with intra-cellular structure.
Ruch and Fulton (1960) defined the holoenzymes as composites of a dialyzable
portion (coenzymes) when a prosthetic group may be separated from the enzyme
by dialysis, and a non-dialyzable protein part (apoenzymes). Bergel (1961) has
elaborated on these families of enzymes which, together with their coenzymes,
metalactivators, metabolicpathways andcycles, differ in theiractivity andpattern
in some tumors from those present in embryonic proliferating and resting normal
tissues.
The word, enzyme, itself was introduced in 1876 by Willy Kiihne (cited by
Wain, 1958) who used it as a general designation for the substances found in
plants and animals which had previously been called soluble or unorganized
ferments, according to Wain's book:
" The Story Behind the Word
" (1958).
Since 1955, it has been clearly evident that no guiding hand presided over the
rapidly growing science of enzymology and only limited relationships could be
claimed with cancer because of gross confusion in unit definitions, nomenclature
disagreements and the multiplicity of terms employed. In 1961 international
agreement was finally reached (Report of the Commission on Enzymes, I.U.B.,
1961), but full international acceptance is still to come (King and Campbell,
1961 ; Freeman, 1961 ; Thompson, 1962).
The report of the Commission on Enzymes of the International Union of Bio-
chemistry submitted and approved in 1961 after prolonged and arduous work on
the part of the commission along with extensive correspondence with biochemists
throughout the world, has the embodiment ofits recommendations in this review.
The scheme of classification of enzymes as oxidoreductases, transferases, hydro-
lases, lyases, isomerases and ligases serves as a reference framework and, the
popular name, the new trivial name and, on occasion, an abbreviation are em-
ployed to minimize confusion.
OXIDOREDUCTASES
Oxidoreductases, which comprise more than 25 per ceiit ofthe known enzymes,
bear a positive but limited significance to cancer. Relatively few enzymes from
this group are altered in cancer, but these may supplement histologic findings
and may or may not indicate the organ origin of the tumor. Oxidoreductases
are diagnostically non-specific in localized or disseminated neoplasia and, to
variable degrees, are influenced by disease states other than malignant iieoplasia.
Dehydrogenases, reductases and oxidases are part of this class.
Lactic Acid Dehydrogenases (Lactate Dehydrogenases), LDH, have beeli
very extensively studied to establish a relationship to cailcer, since wen known to
be normal components of tissue and all body fluids, as weR as being responsible
for forming lactic acid in glycolysis and for oxidation of lactic acid in respiration.
In short, LDH is known to occur in all known glycolyzing cells (Long, King and
Sperry, 1961 ; Fishman, 1960a, b). Currently many investigators have reported
on the structural differences among LDH fractions, forexample, Hill (1958, 1961),
Plageman et al. (1960), Wroblewski (1958a, 1959b), Nisselbaum and Bodanskv
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Schwert (1958). Up to five iso-enzymes have been indisputably demonstrated by
various electrophoretic and cbxomatographic technics (Sayre and Hill, 1957 ;
Hill) 1958. 1961 ; Wieme, 1959a; Starkweather et al., 1961 ; Vesell and Bearn,
1961 ; W6rner and Martin, 1961 ; Latner and SkiRen, 1961; Dioguardi et al.,
1961b; Laursen, 1962). These findings may indicate the specific tissue from
which they derive and such data would enable the chnical chemist in the future
to not merely report an LDH activity in the patient but supply the cancer
diagnostician with the cellular source from which originating. This kind ofdiag-
nostic potential becomes obvious since LDH is elevated in most cancer as well as
many other diseases and consequently is not an adequate screening test per se.
LDH in abnormallevels inbody fluids has beenreported in relation to leukemia
(Hill and Levi, 1954 ; Bierman et al., 1957 ; Wroblewski et al., 1957 ; Bodanski,
1961), gastric cancer (Schenker, 1959), lymphomas (Bierman et al., 1957 ; Wrob-
lewski et al., 1957), central nervous system involvement by metastatic carcinoma
(Wroblewski et al., 1957) and in most malignant tumors (Wroblewski and LaDue,
1955; White, 1958a, b; Van Rymenant and Tagnon, 1959a; Fylling, 1961).
Wroblewski (1958a) reported several different mechanisms to explain the
alterations in LDH activity in serum, serous effusion and cerebrospinal fluid.
Understanding of known mechanisms contributing to LDH activity alteration
in body fluids becomes necessary in order to correlate the quantitative and serial
changes in LDH activity with experimental and/or clinical factors.
Hill and Levi (1954) reported the first important claim that LDH activity was
elevated in individuals with neoplastic disease and inspired much research to be
centered around LDH ever since.
Reviewing the observations of most investigators since 1956 indicates that
severaltypes ofneoplastic diseases seem associated thhigh LDH levels and that
the degree of elevation appears related directly to the extent of spread of the
neoplastic process. In fact, the elevated amount of LDH activity seems appar-
ently uncharacteristic of the mahgnant ceR itself and probably a reflection of
itsrapidgrowth rate and more active metabolism. This seemsthe realimportance
ofmeasuring LDH activity at this time.
Malic Acid Dehydrogenases (Malate Dehydrogenases), MDH, have only beeii
investigated in body fluids to a limited extent. Kdrcher (1962) reported recently
in his well-documented article:
" Die Bedeutung der Enzymdiagnostik in der
Strahlentherapie ", that the value of enzymological diagnosis during radiation
therapy of patients with tumors should be stressed. He employed MDH and
LDH as regulators of his radiation treatment and stated that constant control
of these two enzymes in serum could give valuable clues as to the negative or
positive effects of radiation therapy on the tumor.
Some attention in recent years has also been devotecl to understa'nding and
demonstrating up to three isoenzymes of MDH (Vesell and Bearn, 1958).
Isocitrate Dehydrogenases, ICD, have received the most attention of any
enzyme in the citric acid cycle (Bodanski, 1961). Wolfson and Williams-Ashman
(1957) developed a method for determing ICD activity and Wolfson et al. (1958),
and Sterkel et al. (1958), reported that levels of this enzyme were often elevated
in mahgnancies with metastases to the liver, but were seldom changed in portal cirrhosis and in extrahepatic obstruction of the common bile duct.
Although at this stage, ICD is not generaRy considered ofsignificant value in
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(1961), namely: the marked rise in seriim ICD and the enlargement of the liver
were consistent with rapid metastatic growth of tumor in the liver during the
terminal period of the patient's life.
Tyrosinase (Catechol Oxidase), the enzyme of many names ; phenolase, phenol
oxidase, DOPA oxidase, catechol oxidase, potato oxidase (Long et at., 1961),
but assigned a new systematic name (Report of the Commission on Enzymes,
I.U.B.. 1961), o-diphenol: 02 Oxidoreductase, and herein referred to by its
trivial name, catechol oxidase, has been designated an enzyme under genetic
control (Strauss, 1960) which contains copper. Winkelman (1961) stated that
this enzyme wasfulfilling aspecial role injuvenile melanoma conditions. Earlier,
Fitzpatrick (1952) hadreported that the catechol oxidase reaction appeared to be
associated with the malignant character of human pigment cells, called melano-
genocytes, and of the malignant neoplasms, melanoma cells alone formed melanin
incubated in tyrosine, while other malignant tumors tested contained no catechol
oxidase activity.
It was further shown by Fitzpatrick (1952) that nonmalignant pigment cells
in normal skinrequired activation ofthe catechol oxidase system by astimulating
factor, for example, radiant energy, in order to form melanin when incubated
in tyrosine. Such a catechol oxidase reaction therefore may provide a new
approach to (first) the diagnosis of mahgnancy in pigment-cefl neoplasms, for
example, functional nevi versusmalignantmelanoma, and (second) the differentia-
tion of amelanotic malignant melanoma from other higbly undifferentiated
malignant lesions which it simulates, such as fibrosarcoma, lymphoma and
squamous-cell carcinoma.
Suceinic Acid Dehydrogenase (Succinate Dehydrogenase), SDH, has excited
much curiosity in recent years, largely because of the reported possibihty by
Kaufman and Hill (1960) that SDHactivity inmalignant cellsmight besignificant
since SDH was reduced in infected HeLa cells, a strain of human epithelium
derived from carcinomatous tissue of the cervix. Even more recent, De et al.
(1962) supplemented the information on this flavoenzyme when they reported a
nucleolar localization ofSDH in both normal andmalignant cells fromepidermoid
carcinomatous tissue of human cervix, this being a new finding apart from its
well established cvtoplasmic counterpart, suggesting the possibility ofisoenzymes
existing.
Cytochrome Oxidase, CO, has remained notable for its negative activity in
cancer. Hoffman et al. (1951) reported, as a result of cytochemical studies, that
human leukemic cells and those with lvmph nodes affected by Hodgkin's disease
contained approximately the same degree of CO activity as their normal counter-
parts. Greenstein et al. (1944) had previously reported the same findings with
human leukemia patients. Some investigation is proposed to clarify by explana-
tion why cytochrome oxidase activitv is unaffected b conditions of leukemia.
V y
Glucose-6-Phosphate Dehydrogenase, a glycolytic enzyme, has been widely
investigated by researchers in the field of intermediate metabohsm because of its
role as catalyst in the first step ofthe pentosephosphate cycle. Stave and Oehme
(1961/62) have reported this enzyme significantly decreased in parablastic leuk-
emia. Pearse(I960) hasreportedfrom hisstudiesofgrowingtumorsandespeciaRy
in squamous carcinoma,greatlyincreased activitv ofalucose-6-phosphatedehydro-
genase observed in the ceBs of the growing edge.
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another catalyst in the pentosephosphate cycle has been onlyrecently catapulted
into importance in cancer because of the promising work of Bonham and Gibbs
(1962) who have proposed and described a new enzyme test as an aid in the
diagnosis of gynecological cancer in wbich the increased activity of PGD in
vaginal fluid has significance. According to their investigation, the diagnosis of
cancer appeared to be equaRy as effective in cases of corporeal adenocarcinoma
and mesodermal tumors as with carcinoma of the cervix, including carcinoma-
in-situ. This enzymological approach offers an alternative to the estabhshed
and acknowledged important cytodiagnosis of early cancer of the uterus by
providing a simpler, less expensive, but consistent biochemical screening test
that may disclose more than the histologist can demonstrate regarding possible
metabolic changes in cancerous and precancerous cells. Furthermore, enzymo-
logy and cytology can both afford to explore in greater detail the exfohated cells
from the female genital tract. Other than this report, predominantly negative
results have been obtained by various research groups and consequently., PGD
has been considered only physiologicaRy interesting. Weber (1959) reported
PGD had merit as a functional test in bis study ofhepatic enzymes as related to
pathology of glucose-6-phosphate metabolism. Van Rymenant and Tagnon
(1959a) reported normal values ofPGD activity found inpatients with carcinoma
of the breast and extensive metastases as weR in patients with carcinoma of the
prostate.
GlyceraldehydephosphateDehydrogenases (Triosephosphate Dehydrogenases),
TPD, have become important glycolytic enzymes in recent studies. Stave and
Oehme (1961/62) have reported TPD as consistently decreased in patients suffer-
ing from acute parablastic leukemia when isolated leukocytes were examined
for determination of enzyme patterns, but to a lesser extent than glucose-6-
phosphate dehydrogenase on the same patients.
Glutathione Reductase, GR, activity has few reports in the literature dealing
with its specificity, but it seems predestined to play some role in the cancer
mechanisms of the body. Manso and Wroblewski (1958) reported GR an im-
portant enzyme in oncology. They stated increased serum GR activity was
detected in patients with carcinoma usually in the dissemiinated phase of the
disease, but extention ofthese observations on the relationship of GR activity of
serum, cerebrospinal fluid and serous effusions to cancer and various diseases
would be necessary in order to evaluate the clinical significance of alterations of
GR activity in body fluids. Van Rymenant and Tagnon (1959b) reported in-
creased activity of GR had been observed in the serum of patients with cancer
usuaRy of the generahzed type, whereas lymphomas were not accompanied by
increases ofGR activity in serum. They furtherreported that a few studies were
conducted on enzyme activities in serous effusions, suggesting that the enzyme
activity was increased only when mahgnant cells were present in the effusion.
Catalase activity studies have been carried out by numerous researchers with
divergent opinions on this hemoprotein enzyme. Bergel (1961) made several
references to its possible role in human cancer based on the knowledge that the
catalase tevel decreased continuously during the growth of the tumor, unless the
neoplastic growth was surgically removed when the enzyme regained, after a few
days, its normal level. Such a behaviour suggested inhibitor characteristics.
Feinstein and Vetter (1961) attempted to employ catalase as a cancer therapeutic
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reduced the initial liver catalase activity much more than it reduced the increased
activity obtained on incubation, showing that there was a potential catalase
activity in animal liver which was not detectable by estimating the level of the
enzyme.
Bodansky (1961) in his discussion of serum enzymes corresponding to meta-
bolically involved tissue enzymes cites that too few instances of human plasma
catalase have been studiedand, ofseveral carcinoma cases fonowedenzymatically,
findings for catalase activity were not elevated. Kidson (1962) reported certain
variation in catalase activity in human leukocytes, finding activity of normal
granulocytes higher than that ofnormal lymphocytes. He found levels in para-
myeloblastic leukemia and chronic myeloid leukemia higher than in normal
granulocytes.
Xanthine Oxidase, XO, a purine metabolizing enzyme that displays equally
low activity in normal and cancerous female breast tissue, has been seriously
studied since its introduction by Figge and Strong (1941) who claimed it had a
role in cancer. Much data has been furnished by Bergel (1961). Skepticism
and much controversy have foRowed the report of Figge and Strong aforemen-
tioned. General agreement existed that although XO might be related to the
carcinogenic process, this enzyme could be eliminated almost completely from
the liver by dietary means alone without cancer resulting. From the current
literature it is not known whether the recent claims by Weber (1961), Bergel
(1961) and Bennet et al. (1960), that tumor XO activity is slightly lower than
normal is due to presence of less enzyme or, to the presence of an inhibitor of
XO, or to the absence of an essential activator or auxilliary system. Further
definition of this deficiency might lead to a chemotherapeutic means of over-
coming the deficiency.
Tryptophan Peroxidase, TPO, has been studied rather widely by enzymo-
logists and chemists interested in tryptophan metabolism (Posnanskaya, 1958;
Douglas, 1959, unpublished results; Chan et al., 1960 ; Long et al., 1961 ; Bergel,
1961). TPO ofthe liver is considered an adaptive enzyme controllingtryptophan
metabofism and theoretically with such a relationship to an essential amino acid,
an understanding of its role in disease is necessary. Evidence presented by
Posnanskaya (1958) suggests that theadaptive increase ofTPO system ofthe liver
may not be associated with de novo synthesis ofprotein. Theperoxidase reaction
is used in several forms toattempt differentiation between the later
" blast
" forms
of lymphoblasts and myeloblasts, particularly in acute leukemia. Peroxidase-
positive granules may be present in the cytoplasm of blast cells of the granu-
locyte series and very early pre-myelocytes before ordinary granules are visible
and they are never present in lymphoblasts. Such a laboratory method is of
limited value and shoudd be left to the discretion of the pathologist. There are
also TPO tests for differentiating early white blood ceR precursors in defining
leukemoid reactions. D-Aminoacid Oxidase, a flavoprotein, is an oxidoreductase
that may emerge as a vital enzyme in understanding cancer but it is stin physio-
logically unclarified (Long et al., 1961) but thought to behave as an apoenzyme
(Bergel, 1961).
Bover and Candela (1961) and Candela and Bover (1961) cytochemicany
studied dehvdroLyenaseactivity ofleukocytes andtbxombocytes in blood ofnormal
subjects affected with cbxonic myeloid leukemia and those with polycythemia
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due to unspecific dehydrogenase) of the polynuclear leukocytes occurred in the
cases of myeloid irritation and that a decrease occurred in the case of cbxonic
myeloid leukemia. These findingsparalleled changes observed in alkahne phos-
phatase activity.
Other recent contributions have been made which deserve mention in the
review of cancer enzymology as related to oxidoreductases: Bergel (1960),
Beck (1958), Blanchaer, et al. (1958),Bodansky (1956,1958, 1959), De Lamirande
et al. (1958), Dalgliesh (1952), Efliot and Wilkinson (1961), Frei et al. (1961), Green
(1958), GrbnvaR (1961), Hayaishi (1962), Hfll et al. (1956), Hill and Jordan (1957),
Holmberg and Laurell (1951), Hsieh et al. (1955, 1956), Hsieh and Blumenthal
(1956), Humoller et al. (1958), Jagt and Larsen (1960), King (1957), Kirkeby and
Prydz (1959), Laursen (1959, 1962), Meister (1950), Plummer and Wilkinson
(1962), Rapp and BeR (1961), Riley and Wroblewski (1960), Robert and Van
Rymenant (1961), Singer and Kearney (1957), Stekol (1959), Vetter (1961),
Wieme (1959b), Zucker and BoreUi (1958), and Wroblewski (1958).
TRANSFERASES
In this category may be hsted many enzymes that have been mentioned
in relation to cancer, but always as non-specific enzymes for neoplastic disease
and usuaRy affected by many other disease conditions.
Glutamic Oxaloacetic Transaminase (Aspartate Aminotransferase), GO-T,
and Glutamic Pyruvic Transaminase (Alanine Aminotransferase), GP-T, are
most pronunent in this class. Elevations in GO-T and GP-T activity levels have
been associated with amultiplicity ofdiseases (Wroblewski, 1959a), but may have
diagnostic importance when carefully correlated with chnical facts. Examples
are metastatic and primary hepatic carcinoma which become reflections of the
enzyme changes at the intraceRudar tissues.
GO-T and GP-T serum levels are always increased in diseases involving
destruction of liver cells. Transamination itself, the reaction between an alpha-
amino acid and an alpha-keto acid tbxough which the amino group is transferred
from the former to the latter, has a tendency to relate tumors to protein biosyn-
thesis and degradation if the concept that apoenzymes are products of certain
polypeptides which are products of ribonucleic acid and nucleotides. Extensive
biochemical studies of enzymatic transamination have overshadowed chnical
imphcations of GO-T and GP-T activity in humans, yet these transaminases are
readily measurable by comparatively simple techniques (Karman et al., 1955 ;
Henley and Pollard, 1955 ; Laursen and Espersen, 1.959 ; Laursen and From-
Hansen, 1958; Wroblewski, 1958b, 1959a; Aspen and Meister, 1958). Trans-
aminases appear to be measures of cefl damage rather than cen function and can
be regarded as normal intracellular enzymes. Eastham (1960) stated that when
patients have infiltration oftheliver, cases ofcarcinoma, leukemia andlymphoma
may show an increased activity.
In more recent years, other transferases have received much attention but
so far not achieved major significance. Phosphoglucomutase, PGM, the glyco-
lytic enzyme (Colowick and Kaplan, 1955) that converts glucose-l-phosphate to
glucose-6-phosphate and requires glucose-1, 6-diphosphate as cofactor (Fisbman,
1960b), a reversible conversion, has been reported as elevated in patients with
metastatic disease (Bodansky, 1961) and bears a consistent abnormal pattern in
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tion of PGM activity in serum and has applied it successfully to the chnical
investigation of cancer of the breast. PGM occurs in aR cells (Fishman, 1960b ;
Long et al., 1961) and Nigam et al. (1962) have reported on limiting enzyme
factors for glycogen storage in tumors and show-n the lesion was a defective
system for glycogen synthesis owing to low activities of the enzymes involved
in the synthetic process (PGM and glycogen synthetase) which were unable to
accomplish efficient transformation and catalytic action in the presence of com-
peting high rates of tumor glycolysis and normal polysaccharide degradation by
phosphorylase.
Hexokinase, HK, an enzyme transferring phosphorus-containing groups and
catalyzing the phosphorylation of glucose to form hexosemonophosphate, has
been reported significant in leukemia. Stave and Oehme (1961/62) have demon-
strated decreasedactivity ofHK to 50 per cent ofnormal inparablastic leukemia.
Beek (1958) also has reported HK deficiencies in leukemic cells, pointing out
that the phosphogluconate oxidation pathway occurs in leukocytes, though less
than 10 per cent of utilized glucose traverses this pathway and this percentage
being higher in leukemic cells than in normal cells. The extent of alternative
pathwaymetabolismis shownto beunder direct control oftheglucose-6-phosphate
concentration and indirect control of the hexokinase level. Beck states the
higher percentage of phosphogluconate pathway metabolism in leukemic cells
can be attributed to their deficiency ofhexokinase.
Pyruvate Kinase, PK, an enzyme catalyzing an essential step in the glyco-
lytic or fermentative breakdown of carbohydrates (Long et al., 1961) has so far
very limited apphcation in clinical medicine and based on the current literature
(Bodansky, 1961), because much attention has been directed toward theinvestiga-
tion of PK in blood, it is noteworthy to say that this enzyme remains insigni-
ficantly altered in advanced cancer and widespread metastases.
Ornithine Carbamoyltransferase, OCT, an enzyme incompletely studied,
but theoreticaRy looming as a diagnostic potential of value in neoplastic disease
of liver and other organs, remains to be developed. Reichard (1957) has reported
a dependable laboratory method for the determination of OCT by a micro-
diffusion technique.
Phosphofructokinase, PFK, an enzyme related to KH, was studied by Neu-
fach and Melnikova (1958) who reported considerable data to support the theory
that while the rate of glycolysis in skeletal muscle does rely upon PFK power,
it is really a function of HK in erytbxocytes and tumors.
Phosphoribokinase, PRK, another enzyme related to HK, was introduced in
1953 by Scarano and considered to be altered in tumor growth due to direct or
indirect involvement ofPRK in formation ofadenosinemonophosphate in animal
tissue from adenine (Saff-ran and Searano, 1953).
Ribonuclease, RN, the enzyme that catalyzes the hydrolysis of ribonucleic
acid, figures only indirectly in cancer, but much speculation has been reported
over the past ten years on this physiologicafly important nucleolytic enzyme
(Greenstein, 1954 ; Allard et al., 1957 ; Houck, 1958 ; Dixon and Webb, 1958
De Lamirande et al., 1958 ; De Lamirande and Allard, 1959 ; Fishman, 1960b
Long et al., 1961 ; Josefsson and Lagerstedt., 1962) and it has even been reported
in recent literature that there exist several isoenzymes of RN which differ in
their pH optima, their tissue origin or their nucleotide end-products (Bergel,
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Galactose-l-Phosphate Uridylyltransferase, an enzyme possibly under genetic
control has been proposed as indirectl having a role in the mechanisms of
cancer enzymology (Strauss, 1960).
Some relationship has been suggested between tumor development and
enzymes ofthefatty acid metabolism but so far is too purely chemical to interest
becologists (Stern et al., 1956a, b ; Robinson et al., 1957). Most transferases
ionng intraceRular, exert minimum diagnostic value for the clinician.
HYDROLASES
In this very large class of enzymes a positive relationship has been displayed
in cancer by some hydrolases, whereas other incompletely documented hydrolases
appear insecurely linked to the field of cancer. So much has been written about
certain enzymes in thisgrouping, that only the pertinent data and current reports
need be reviewed.
Acid Phosphatase, ACP, an orthophosphoric monoester phosphohydrolase,
an enzyme that liberates inorganic phosphate from phosphoric esters with an
optimum pH of 5-4, is almost synonymous with the prostate gland. An impres-
sive and lengthy list of standard literature has accumulated over several decades
(Kutscher and Wolbergs, 1935; Gutman and Gutman, 1938; Gutman, Gutman
and Robinson, 1940; Huggins and Hodges, 1941; Gomori, 1941; Abul-Fadl
and King, 1948; Herbert, 1946; Woodard, 1952, 1959; PoweR and Smith,
1954; Bonner, Homburger and Fishman, 1954; Bodansky, 1954a, 1959, 1961 ;
Nylander. 1955; Mather, Richmond and Sprunt, 1956; Fishman and Davidson,
1957; Fishman, 1960a; Pearse, 1960; Benson, 1957; Bergel, 1961 ; A-nnino,
1960
- Zucker and Borelli, 1959; Long, King and Sperry, 1961 ; Meijer, 1962).
It is redundant to say this enzyme is extremely important in the diagnosis of
metastasizing carcinoma of the prostate. Gutman and Gutman (1940) having
reported from their data that increases to several hundredfold over the normal
range for ACP activity were noticeable in subjects with prostatic carcinoma espe-
cially when the tumor extended outside thegland. ACP estimations aregenerally
made either by the quantity ofphenol Eberated from sodium phenylphosphate,
as in the King-Armstrong method, or by the liberated phosphate from glycero-
phosphate, as in the Bodansky method. Fishman and Lerner reported in 1953
their well known method for
" prostatic
" acid phosphatases which gave excellent
correlation with the presence of proven cancer of the prostate (Fishman, Bonner
and Homburger, 1956; Fishman et al., 1953). Fishman et al. (1953) reported
evidence that, by means of an 1-tartrate inhibitor, one could measure largely, but
not exclusively, prostatic acid phosphatases based on both experimental and
chnical data. In the numerous attempts to render the ACP determinations more
specific for prostatic origin, the works of many investigators are noteworthy.
Reynolds et al. (1956) used copper to inhibit erythrocyte ACP and reported a
large percentage of patients with widespread cancers of the female breast or of
the prostate gland had significantly elevated values for copper resistant ACP.
Abul-Fadl and King in 1948 employed a simple formaldehyde treatment to
distinguish between the high ACP of prostatic origin and those accompanying
other conditions. while earlier Herbert in 1946 hadreported employing an alcohol
incubation treatment for the same purpose. Gray (1959)reported that theplasma
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alcohol and this behavior useful in deciding whether an increased ACP activity
level was due to prostatic carcinoma or to liberation of the ACP from red blood
ceRs by hemolysis. Woodard (1959) reported it possible to distinguish rather
clearly between the level of the prostate and that of the erythrocytes, but not so
simple to distinguish between prostatic ACP and acid phosphate from other
sources. Zucker and Borelh (1958) reported normal serum acid glycerophospha-
tase appeared to come from blood platelets. In contrast to normal individuals,
acid glycerophosphatase activity was found in serum from platelet-poor plasma
obtained from patients with metastatic carcinoma of the prostate, suggesting
that a more sensitive test for pathological elevation of this enzyme activity in
prostate cancer was provided when the contribution of ACP from the platelets
was avoided. Methodology has undergone critical examination over the years
and the results render accurate and sensitive data.
Regarding the possible isoenzymes ofACP, Meijer in 1962 reported three dif-
ferent non-specific fractions characterized by different pH optima between 3-4
and 5-8 in the liver and spleen after intraperitoneal administration of macro-
molecular substances as Dextran and Polyvinylpyrrohdone, which caused the
entire enzyme complex to rise. Meijer also noted the increase in activity was not
equaRy distributed.
Part of the clinical value of this enzyme is not only to detect the occurrence
of metastases in this prostatic disease, but to assess the progress of therapy in
such cases (Harper, 1958).
Much work and study have gone into the relationship of ACP to mammary
cancer (Reynolds, et al., 1956 ; Lemon et al., 1958 ; King, 1959 ; Eastham, 1960 ;
Fishman, 1960b) with moderately positive, but questionable findings. Reynolds,
Lemon andByrnes(1956), thenLemon,Reynolds and KeUey(1958) claimed when
using copper-resistant ACP that 74 per cent of a group of female patients with
mammary metastatic carcinoma had elevated enzyme levels. Lemon and
Wisseman (1949) by employing histochemical and quantitative microchemical
methods reported carcinoma ofthe breast, bronchus, skin, bladder and gastro-
intestinal tract were richer in ACP than the tissue of origin. Such reports were
in agreement with earher histochemical studies on human tumors by Gomori
(1941). Hudson et al. (1955) demonstrated that liver appeared to be imphcated
in the metabolism of serum ACP ofprostate origin and found values grossly ele-
vated (over 1000 Gutman units per 100 ml. plasma) in cases with metastases of
the liver from prostatic cancer. Burstone (1958) demonstrated that lung carci-
noma showed, by an azo-dye histochemical staining technic for ACP, groups
and masses ofintensely-staining neoplastic ceRs and indicated that this common
characteristic of lung tumors might be a useful tool in studying bronchial aspira-
tions.
Adventitious elevations of ACP have appeared frequently in the literature
(Hock and Tessier, 1949 ; Woodard, 1952 ; Fishman et al., 1953 ; Bonner et al.,
1954 ; Dybkser and Jensen, 1958 ; Bodansky, 1961 ; Ladehoff and Rasmussen,
1961). It has been noted that massage, palpation, trauma, rectal examination or
any pressure exerted on the prostate may result in sudden elevation of the ACP
activity level. This occurrence seems best comprehensively supported by the
theory of Ladehoff and Rasmussen (1961) who stated that very hkely the in-
creased fibrinolysis in blood observed in transvesical prostatectomy was caused
by a release ofprostatic tissue activator into circulating blood during the mani-426 W. R. DOUGLAS
pulations of enucleationtogether withdamage ofandadsorption from theparticu-
larly active
" surgical capsule ", which was the site ofcleavage.
AlkahnePhosphatases,ALP, have been socompletelyreviewedin the literature
by Bodansky (1961) and supplemented to such an extent (Franseen and McLean,
1935 ; Gutman et al., 1936 ; Bruns and Jacob, 1954 ; Bodansky, 1956, 1959 ;
Schlamowitz and Bodansky, 1959; Gutman, 1959; Gray, 1959; Fishman,
1960a; Fischer and Siebert, 1961 ; Barnes and Cope, 1961) that condensation
of aR published reports would be difficult. ALP activity levels are commonly
elevated in osteogenic sarcoma, in metastatic carcinoma to bones resulting in
osteoplastic changes, in myelogenous leukemia, in carcinoma of the pancreas, in
hyperparathyroidism accompanying cancer of the parathyroid glands and in
hepatic disorders such as secondary carcinoma. lwatsuru and Nanjo (1939)
reported elevated ALP activity in blood of a chronic myeloid leukemia patient.
lwatsuru and Minami (1934) reported normal values for ALP in acute lymphatic
leukemia. Xefteris et al. (1961) reported the prognostic significance of enzyme
levels in the remissions of chronic granulocytic leukemia patients treated with
Busulfan (Myleran) therapy, presenting data suggesting the return to normality
of ALP activity might presage a lengthy remission. This parameter was based
on twelve cases. However, King (1957) stated no useful correlation of ALP in
leukocytes was possible with cancer.
A contribution to the study of serum ALP and its role in cancer has been made
by Chevillard in 1945, who demonstratedplatelet phosphatase entering the serum
during clotting, this source being more extensively elaborated upon in more
recent work of Zucker and Borelli (1958, 1959). CheviHard's report stimulated
many other investigators apparently, because other important reports were
published subsequently by Wachstein in 1946 and Valentine in 1956 on the role
ofALP in blood. Before 1945principalknowledge ofleukocyte ALP activity was
attributed to Kay who introduced same in 1930 and the work of Roche (1931),
then Fiessinger and Boyer (1935).
Gutman (1959) pointed out the limitations in presently considering serum
ALP determinations in the differential diagnosis of hepatobiliary diseases ;
referring, among other references, to the failure to distinguish obstruction of
the intrahepatic from that of the extrahepatic biliary tract, and the failure to
differentiate benign from malignant occlusion of the extrahepatic biliary tract.
Regardless, alkaline phosphatase activity determinations are the most sensitive
available chemical criterion ofextra-, or intrahepatic biliary tract disorders.
Kerppola (1951)reported nosimple correlation has been shown to exist between
tumor growth and the concentration of phosphatase in ordinary tissue; and,
as regards the origin of the phosphatase in the blood cells, it was of interest that
no correlation was observed in cases between serum phosphatases and the blood
cell phosphatase. Kerppola further reported in detail on the presence of par-
ticular phosphatases related to ceRular reaction, claiming that some phosphatase
might destroy cells or their nuclei, that some phosphatase activit was purelv
physiological, that some phosphatase concentration was related to accelerated
or malignant growth of bone marrow of tissue associated with bone formation;
and that bis observations disclosed many unexplained appearances of phospha-
tase activity in blood and bone marrow cells.
Gutman (1959) emphasized the distinct value of an increased ALP activity in
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that because the humai-i prostate produces an alkaline phosphatase which is
capable ofbeing inhibited by tartrate in contrast to the enzyme in erythrocytes,
this difference could be used for diagnostic purposes in cases of prostate cancer.
Decreasing values in serum ALP activity can be interpreted as enzvmological
evidence ofrelapsing disease (Myers and Bodansky, 1957) and such has been also
described by Griboff et al. (1954), as heralding the onset of hypercaleemia in
carcinoma of the breast which in turn may indicate exacerbation of the disease.
Keiding in 1959 reported three different ALP activities in serum by zone
electrophoresis technics in his studies on cancer patients although from a hetero-
genous group. Although iio more than three types of ALP activities have beeii
observed bv any one method to date, whether starch granule electrophoresis or
cellulose chromatography or immunological systems, Boyer (1961) has recently
reported that at least 16 bands of non-specific ALP activities were evident in
human serafollowing electrophoresisprocedures on hydrolyzed starch gel, but not
all occurred in a single individual. Moss in 1962, using butanol-extracted liver
preparations, showed variations in thepattern ofA-LPisoenzymes,probably due to
methodology. Hodsoii et al. in 1962, continuing their previously reported isoeli-
zvme work (Hodson et al., 1961), claimed tissue-specific alkaline phosphatase
isoenzymes were found. lt is necessary for additional research along these lines
to show the relationship of these ALP components in differential diagnosis of
cancer.
Much speculatioii has centered around another phosphatase (Long et al.,
1961), 5-Nucleotidase, 5NT, which is optimally active at an alkaline pH and has
ai-i alteratioii in many disease states (Bergel, 1961 ; Bodansky, 1961 ; Young,
1958 ; Van Rymenant and Tagnon, 1959b). Dixon and Purdom (I954) reported
5NT activity level low in osteogenic tumors, breast cancer and spinal neoplasms.
I'an Rymenant and Tagnon (1959b) stated the diagnostic value of 5NT deter-
mination could be advantageous in comparison to ALP because it was uniii-
fluenced by bone disease. 5NT determinations may prove to be of clinical value
in view of the evidence that it is at least as sensitive as the serum ALP in detect-
ing the presence ofbiliary tract obstructions and is more selective because values
are not increased in disease ofbone associated with increased osteoblastic activity.
Beta-Glucuronidase is another important hydrolase that has undergone much
scrutiny byinvestigators (Long et al., 1961) and occurs in a wide variety oftissues
with high concentrations found in liver, spleen and endocrine tissues (Fishman,
1960b). Thorough assay methods have been developed (Colowick and Kaplan,
1955 ; Fishman et al., 1948 ; Fishman et al., 1947) and histochemical procedures
(Seligman, Nachlas, Manheimer, Friedman and Wolf, 1949) have demonstrated
both animal and human tumors rich in this enzyme. It has been reported that
the buffy coat of blood has high beta-glucuronidase activity (Fishman, 1960a) ;
and, Anlyan et al. (1950), have studied and reported a wide range of enzyme
activity in various types of leukemia with abnormally high values occurring in
myelogenous leukemia based on their patients with leukemia and Hodgkin's
disease. Fishman et al. (1947) found strikingly elevated values in many human
neoplasms and above normal values in the vaginal fluid of a large percentage of
women with cancer of the uterine cervix (Fishman et al., 1954). Beta-glucuroni-
dases are elevated inprimaryneoplasms ofthebreast, uterus, ovary, stomach colon
and in their metastases to other organs and lymph nodes. There is a correlation
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under certain conditions and between the activity ofthis enzyme in exudates and
the presence of cancer (Homburger and Fishman, 1956). Elevations in cases of
cancer ofthe breast are common (Cohen and Huseby, 195la, b ; Fishman, 1960b )-
Fishman et al., 1954). Much research has been performed and wiR be continued
towards understanding this hydrolase (Fishman, 1949; Fishman and Anlyan,
1947 ; Fishman et al., 1959 Fishman and Bigelow, 1950 ; Homburger, 1960 ;
Fishman and IvEtchell, 1959 Bodansky, 1961 ; Boyland et al., 1957 ; Rauramo,
1959a, b ; Odell et al., 1949 Kasdon et al., 1950 ; Kasdon et al., 1953).
There are numerous otherhydrolases which have so far an insignificant role in
"general cancer but mayfigure moreprominently inthe future; as, Arylsulphatase
(Dzialoszynski, 1957 ; Dodgson and Spencer, 1957 ; Dodgson et al., 1956 ;
Tanaka et al., 1962), Amylases (Ende, 1961 ; Best andTaylor, 1961 ; Hansen and
Jacobsson., 1952; Jacobsson and Hansen, 1952; Jorgensen and Svendsen, 1961),
Adenosine Deaminase (Schwartz and Bodansky, 1959 ; Stekol, 1958 ; Straub et
al., 1957), Glucose-6-Phosphatase (Weber'1959 ; Weber andCantero, 1960 ; Kit,
1960),Arginase(ForsellandPalva,1961; FriedmanandBecker,1955; Pravdeena,
1957 ; Roberts, 1948), Plasmin or Fibrinolysin (Long etal., 1961 ; Astrup, 1956),
Elastase (Lewis et al., 1956), Chymotrypsin (Lundh, 1957 ; Billow et al., 1960 ;
Brandborg et al., 1961), Trypsin (Lundh, 1957 ; Astrup and Albrechtsen, 1957 ;
Astrup and Sterndorff, 1955 ; Nardi and Lees, 1958), Pepsin orUropepsin (Gray
et al., 1955 ; Jorgensen, 1954; Bock, 1954; Christensen, 1957a), Deoxyribo-
nuclease (Kowlessar et al., 1953 ; Brody, 1958 ; Brody and Balis, 1958), Leucine
Aminopeptidase (Dioguardi et al., 1961a ; Goldberg and Rutenburg, 1958),
Cholinesterase (Winkelman, 1961 ; Gal and Roth, 1957 ; Torp, 1956 ; Stovner,
1955 ; Sabine, 1951 ; Augustinsson, 1955), Esterases(Green andJenkinson, 1934),
Cathepsins (Libenson and Jena, 1957), and the Lipases (Cohn and Kaplan,
1960 ; Borgstr6m, 1957 ; Bergel, 1961 ; Best and Taylor, 1961).
LYASES, ISOMERASES AND LIGASES
Relatively few lyases bear significance to date. Most noteworthy are aldo-
lase, hyaluronidase, carbonic anhydrase, tryptophan synthase, hydroxytrypto-
phan decarboxylase and possibly ketotetrosealdolase. The latter enzyme has
been confused biochemically with aldolase (Wolf, Forster and Leuthardt, 1957)
and is only negatively important in that it is consistently absent from serum in
instances of liver metastases and normal serum, although appearing in serum of
patients with viral hepatitis and other diseases. Hydroxytryptophan Decar-
boxylase has been examined by many protein and enzyme researchers (Cantero,
1955 ; Douglas, 1959, unpublished results; Kizer and Chan, 1961 ; Kizer, 1962)
whohave related it totheminorpathwayoftryptophan metabolism and correlated
such activity with cancer susceptibility, not yet successfuRy. Along the same
line of investigation, studies have embraced tryptophan synthase (Smith and
Yanofsky, 1962). Summarfly, from the bulk of work done of hyaluronidase, no
true correlation occurs between hyaluronidase content and the type of tumor
(Dux, Guerin and LaCour, 1948) nor from other correlations speculated upon
(Truedsson, 1951 ; Bolio-Cicero et al., 1961 ; Gaines, 1960 ; Winslow and Taylor,
1960 ; Ekman et al., 1953 ; Faber and Schmith, 1950a, b ; Winslow andEnzinger,
1960). Aldolase is a non-specific enzyme, elevated in most cancer conditions, but
also in many other diseases. Baker and Govan (1953) fou-Dd aldolase activity429 ENZYMOLOGY AND CANCER
consistentlyhigh in the serum ofpatients with advanced carcinoma oftheprostate
andexpressed theopinion that this enzyme was a better index than acidphospha-
tase for the evaluation of the status of the patient. Much earlier work was done
by Sibley and Lehninger (1949) and recent reports have been made by White
(1958a, c) and Loken (1956). The fuH diagnostic value remains unestablished
(White, 1958b). Some newlyases areinsufficiently studied toreport (Briiggemann
et al., 1962 ; Briiggemann and Waldschmidt, 1962).
Isomerases, those enzymes in muscle and other tissue that catalyze the conver-
sion of glucose-6-phosphate to fructose-6-phosphate, a reaction of importance in
glycolysis, are indefinitely established in cancer enzymology. Two isomerases
are outstanding at this stage and both could be classified by the organic chemist
as intramolecular oxidoreductases interconverting aldoses and ketoses.
Triosephosphate Isomerase, TPI, has been measured in serum (Colowick and
Kaplan, 1955) ; and, in cases of generalized cancer was positively elevated in
hepatic metastases and occasionally constituted the sole enzyme change in the
serum (Robert et al., 1961). Robert et al., 1961, noted TPI activity level elevated
in cases ofleukemia; but, demonstrated that the value of this determination in
differential diagnosis seemed restricted to the detection of liver metastases in
patients with cancer (Van Rymenant and Robert, 1961).
Phosphohexose Isomerase (Glucosephosphate Isomerase), GPI, has been
studied extensively byBodansky (1954b, c, 1955, 1956) and shown to be raised in
patients with metastatic cancer of breast or prostate and even more interesting,
shown to have an
" isomerase-mutaseactivity ratio
" (Bodansky, 1957b) in serum,
thisproposed as an index ofmetastaticgrowth in the skeletonand/or liver within
certain limitations. The ratio aforementioned was the result of Bodansky's
comparison studies with serum phosphoglucomutase (1957a) and GPI (1957b)
inmetastatic cancer. Animpressivedegree ofcorrelation wasreported(Bodansky,
1954c) to exist between increases in serum GPI activity and growth of metastatic
tumor in bone, as judged clinicaRy, and by biochemical methods, particularly by
the urinary calcium excretion. Bodansky has demonstrated that such GPI acti-
vity can provide a useful index to growth or regression of tumor. Decreases
toward normal GPI levels were associated with evidence of tumor regression
whereas marked and sustained elevations very often preceded widespread meta-
stases and death. but increases in GPI activity after a sequence of repeatedly
normal levels was frequently the first herald of renewed growth of tumor.
Strangely, much of the enthusiasm surrounding this enzyme has subsided in the
past few years.
Israels and Delory (1956) have reported GPI significant in leukemia and,
according to Van Rymenant and Tagnon (1959a), the GPI activity of red blood
cells is 160 times greater than that ofplasma; however, in many types of hemo-
lytic diseases, the GPI activity of plasma was low and contrasting with a high
level ofLDHactivity, thuscreating an increased ratio ofLDH to GPI whichmight
be indicative of the existence of a hemolvtic process in the blood of the patient
(Blanchaer et al., 1958).
Myers and Bodansky (1957) reported a study of a patient with metastatic
cancer of the breast in which two parameters of tumor activity, serum GPI and
urinary-calcium, were determined over a nine-month period. They obtained
high enzyme activity whichpossibly reflected active soft tissue disease in the liver
although there was no biopsy proof of liver metastases.430 W. R. DOUGLAS
White (1958b) concluded that abnormal serum GPI activity might be a result
of, and also an indicator of muscle wasting in many patients with cancer.
Ligases, perhaps better known in enzymology as Synthetases, those enzymes
wbich catalyze the joining together of two molecules coupled with the breakdowii
of a pyrophosphate bond in adenosine triphosphate (ATP) or a similar triphos-
phate (Report of the Commission on Enzymes, I.U.B., 1961), are as a whole uii-
familiar to the cancer enzymologist.
liNFLUENCliNG FACTORS O-N ENZYME ACTIVITIES AND DISCUSSION OF CARCINOCHEMO-
THERAPY
When the work of Braunstein and his colleagues (1958, 1962, 1962a, 1962b)
who have given such detailed reports on their histochemical studies ofenzymatic
activity of lymph nodes and found it possible to identify cells by their enzyme
content as well as further substantiating the classification ofmalignantlymphoma
based upon conventional staining technic; and the work of Brody and his col-
leagues (Brody, 1958; Brody and Balis, 1958) who have shown completely
different paterns of ribonuclease and deoxyribonuclease activities in normal and
neoplastic growth asthey demonstrated apositiverelationship betweenthegrowth
rate of tissue and their RN and deoxyribonyclease activities ; and the works of
Allard, De Lamirande and Cantero (Allard, De Lamirande andCantero, 1957 ; Can-
tero, 1955 ; De Lamirande, Allard and Cantero, 1958 ; De Lamirande and Allard,
1959) who have reported the results of extensive explorations of intracellular
distribution of various enzymes in primary and transplantable liver tumors and
compared those results with those ofazo-dye fed rats and regenerating liver and
noted such enzymes as ACP, ALP, RN, cathepsin, adenosine triphosphatase and
glutamic dehydrogenase disclosed a distinct variation of enzyme pattern in
normal and tumor conditions ; and when other important works reported by
Bergel (1956, 1961), Vetter and Griesche (1961), Vetter (1961), Morton (1958)
and many more are reviewed, it then becomes a postulate that human and animal
enzyme activities in the body are altered in cancer. Specific tumors have pro-
duced certain enzymes ; as osteogenic sarcoma has produced ALP, or specific
organs have secreted, when they are the site of cancer, certain enzymes as
carcinoma of the prostate has secreted ACP, or general or localized reactions
accompanyiiig certain cancers have produced LDH which correlated with the
state and severity of leukemia (Homburger, 1960; Bierman et al., 1955). The
level of activity of beta-glucuronidase in the vaginal fluid is increased in nearlv
every case of cancer of the cervix (Fishman et al., 1954 ; Kasdon et al., 1953).
The level ofactivity ofuropepsin in benign gastric ulcer is high but in 80 per ceiit
of gastric cancers is low (Gray et al., 1955). The presence of tumor and distri-
bution of enzymes are related.
The other factors, chemical and physiological and biophysical, are concisely
stated in textbooks, reference books and various periodicals (Fenton, 1960 ;
Ruch and Fulton, 1960; Long et al., 1961 ; Wolfson et al., 1.958; Wroblewski,
1959a; Wroblewski et al., 1958; Robins, 1957 ; Endahl and Kochakian, 1957 ;
Plummer and Wilkinson, 1962; Mason, 1958; Norberg, 1961 ; Mendelsohn
and Bodansky, 1952; Fishman and Davidson, 1957) in considering factors
influencing enzyme activity for possible cancer applications.
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numerous hepatomas, lymphomas, mammary tumors, rhabdomyosarcomas and
adenocareinomas can provide more extensive background for the enzymic
characteristics of tumors as contrasted to normal tissues than the reports
of Greenstein (1954). Similar systematic studies with human tumor material
have yet to be done due to difficulties in coRecting specimens of human cancer
According topresent status, much more must be understoodregardinginfluencing
factors on enzymes.
Fishman (1960a) stated control of tissue enzyme activity may be genetic,
dietary, hormonal, sexual and substrate adaptation.
There is some difficulty encountered in discussing influences upon enzyme
activity due to variable usage of certain words.
" Impaired
" as used by War-
burg (1956), for an example of confusion, was defined as involving any com-
bination ofthefollowing : a. high rate ofglycolysis torespiration ; b. low absolute
value for oxygen consumption ; c. inefficient or uncoupled respiration ; and, d.
low suceinate oxidative response. Potter (1958) and Weinhouse (1960) had differ-
ent definitions. Interpretations of cancer enzymology were handicapped because
of a lack of exact definition. The summary of Fishman (1960a) presented an
excellent brief account of all the various aspects of tumor enzymoloLyv.
Methodology for foRowing these enzymes referenced and their,
,
influencing
factors are amply covered by many enzymologicaRy oriented scientists (Colowick
andKaplan, 1955, 1962 ; Glick, 1959 ; Annino, 1960 ; Aspen and Meister, 1958 ;
Astrup and Albrechtsen, 1957 ; Augustinsson, 1955 ; Baker and PeRegrino,
1954 ; Karmen et al., 1955 ; Natelson, 1961 ; Seligson, 1961 ; Josefsson and
Lagerstedt, 1962 ; Schlamowitz and Bodansky, 1959 ; Sehgman et al., 1949
Powell and Smith, 1954 ; Thiers and Vallee, 1958 ; Fraenkel-Conrat, 1957
Schmith and Faber, 1950; Tammelin, 1953, Udenfriend et al., 1958; Cohn and
Kaplan, 1960 ; Christensen, 1957a' 1957b; Dawson et al., 1959; Dean and
Woodard, 1947 ; Desnuelle, 1961) impossible to be fuRy hsted. There appear a
continuous stream of new technics superceding, supplementing, complementing
and modifying stock procedures so that enzyme study is fully devoid of stag-
nancy.
Based on the assumption that we have enzyme patterns, it is also simple to
conclude that we have changes during carcinogenesis and/or the metabohsm of
carcinogenic agents. Under this heading, much experimentation has been and
continues to be done by Boyland and his associates (Boyland and Watson, 1956 ;
Boyland et al., 1957; Boyland, 1958) with tryptophan metabolites, and many
recent reports pointed out by Berenblum (1956) and Bergel (1956, 1960, 1961). Unfortunately, there exists a paucity of data deahng with the distribution and
concentration ofenzymes in human tumortissue. CoRaboration between enzymo-
logists, pathologists and chnicians are occurring now and the consequences are
noticeable by a new flow ofvaluable information.
Cancer chemotherapy includes radioactive isotopes, sex hormones, adrenal
steroids, antimetabolites, non-therapeutic toxic compounds, polyfunctional alkylating agents and miscellaneous compounds. Drugs in clinical use, or under
investigation, have been generaRy of limited value. Most investigations from
a chemotherapeutic point ofview have beenperformed on body organs not essen-
tial to life as prostate and mammary glands, thyroid glands, gonads, uterus and
cervix. In the search for specific agents to counteract cancer tissue, enzymes have not fulfilled expectations to assist therapeutically.432 W. R. DOUGLAS
In the comprehensive review ofchnical cancerchemotherapybyWright (1961)
enzymatic therapy was conspicuously absent, and only references made to exces-
sive phosphatase activity found in cyclophosphamide therapy; and, altered
phosphatase values found in androgen control therapy or upon administration of
testosterone. Welch (1961) mentionedspecificaRy the need toexploit theenzymic
deficiencies of tumors and gave several metabolic approaches to cancer chemo-
therapy. Bergel (1961) added further data on enzyme therapy as he pointed
out therapeutic possibilities of xanthine oxidase, ribonuclease, deoxyribonuclease,
lipase and eysteine desulfhydrase. Coordinated studies of chemotherapeutic
compounds and enzyme systems have produced much more rewarding results,
such as the report of Reichard et al. (1962), which demonstrated that certain
enzyme assays will benefit the following of clinical course in chemotherapy, as in
5-Fluorocil treatment, in which they found significance in enzymes of the uracil
pathway during development of resistance. Cohen and Huseby (1951a, b) have
noted estrogen therapy caused a marked rise in the beta-glucuronidase activity
in the sera ofpatients being treated for mammary cancer with maximum values
twice as high as the pre-therapy level. Farber (1955) and Bergel (1960, 1961)
stated that when there was an indicated permanent insufficiency of enzymes, or
their co-factors could be given restitution or replacement for normal status, t11V
need was to provide a holo-, apo-, coenzyme or model system with a specific
enzymic activity.
Streptokinase or plasminokinase (Dixon and Webb, 1958), the activator that
converts plasminogen of blood plasma (Long et al., 1961), an enzyme precursor,
into aproteolytichydrolase, calledplasmin causin-a Ivsis offibrin andliquifaction
of any fibrinous exudate, has been employed therapeutically in man to disperse
such exudates (Bridgwater and Necheles, 1957 ; Fletcher, 1954). Streptokinase
is generaHy considered a product ofhemolytic streptococcal metabohsm, not an
enzyme. Plasmin, formerly known as fibrinolysin, has been used alone and com-
bined with deoxyribonuclease* (Margulis et al., 1961) after much basic develop-
ment by Astrup et al. (Astrup, 1956; Astrup and Sterndorff, 1955; Astrup
and Albrechtsen, 1957), Christensen (1957b), Bridgwater and Necheles (1957)
and Tillett et al. (Tillett and Garner, 1933 ; Tillett, Johnson and McCarty, 1955).
Deoxyribonuclease of bacterial origin has also been employed clinicaRy in the
treatment of purulent exudates (Bergel, 1961 ; TiRett, Johnson and McCarty,
1955). Chymotrypsint, a mixture of pancreatic enzymes (Cigarroa, 1960), was
employed to minimize the edema that followed radical mastectomy and neck
dissection for malignant tumor. Topical applications of proteolytic enzymes
augment the bactericidal properties of the antibiotics in dermatological cases,
performingonly apalliative function. With the medical trend toemploymultiple
aids for a common purpose, and the fact thatproteolytic enzymes achieve no cure
alone ; and certainly, no reliable practical experiences in cancer therapy have
been documented, it is better to refer to certain enzymes as therapeutic adjuncts.
At this point, few investigators have applied present day knowledge of tumor
enzymology to problems that the physician and his patient face in human cancer.
Applied tumor enzymology is undeveloped.
* Elase-Parke, Davis and Company (registered trademark for fibrinolysin-deoxyribonuclease combination).
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Richterichpresented the first full report on the clinical application ofenzymes
in 1958. Preparatory to utifizing enzymes in cancer therapv effectively, inter-
mediate metabohsm must be further explored, especiaRy tryptophan metabofism,
and an interrelationship with carcinogens and enzyme systems programmed.
Although not directly deahng with enzymes in every case, the publications of
certain researchers may serve as general reference ; such as the intermediate
metabolism technics of Dalghesh (1952) Synge and Tisehus (1949) and Robinson
et al. (1957); the cyto-immunological systems of Bj6rklund et al. (1957, 1958) ;
the clinical laboratory methodology of Seligson (1961), Natelson (1961) and
Annino (1960) ; the electronmicroscope applications ofFisher and Fisher (1961) ;
the physical chemistry of Endahl and Kochakian (1957) and Klinkhamer and
Eichel (1962); the antigen studies of Abramoff et al. (1959), Korngold (1960),
Weiler (1959), Witebsky et al. (1956), and Zilber (1958); the specialized meta-
bolic conditions of Beutler (1959), Wheeler and Alexander (1961), Boyland and
Watson (I956), Bro-Rasmussen (I958), Lewis et al. (I959), andStrominger (1960) ;
the comparative chemotherapeutic reports ofVon Euler et al. (1937), AErand et al.
(I961), Hayashi and Fishman (I961) and Cobb et al. (I961) ; the reports on car-
cinogenesis of Elson (1958), Fukui et al. (1961), Reid (1962), Kizer (1962), Kizer
and Chan (1961), Knox (1960) and Warburg et al. (1924). Also, the list could
continue and single out references to enzymatic methods for non-enzyme sub-
stances, as Gjorup et al. (1955), Jorgensen and Chen (1956), Proetorius and
Poulsen (1953) and ReheR et al. (1952) ; references to biochemical procedures as
noteworthyexamples, like Hayaishi (1962), Heilbronn (1953), Huggins and Smith
(1947), Kumick (1962), Lowry (1957), Smith andYanofsky (1962), Wieme (1959b),
Winer and Schwert (1958) and Wolf et al. (1957) ; references to certain histo-
chemical determinations as Winslow and Taylor (1960), Gomori (1957), Winslow
andEnzinger(1960),Waterman(1940)andSehgmanetal.(1949); referencesto
pharmacology and associatedsubjects as Johnson et al. (1954), Heath et al. (1958),
Storm and Nielsen (1958), Timonen and Schroderus (1953) and Werner and Mutt
(1954) ; references to immunology as Nairn et al. (1960) ; references to carbohyd-
rate synthesis as Gaines (1960) ; references to tumor-host relationship factors
as Grace and Lehoczky (1959) ; and more generahzed references, as the effect of
physical stress on enzymes reported by Halonen and Konttinen (1962), patterns
and forms of enzymes reported by Markert and Mbller (1959), employment
of computer analysis as a new diagnostic tool reported by Mason et al. (1961),
discovery of a new
" enzyme
" reported by Murray (1961), speculation on a
probable peptidase reported by Pearse and Pepler (1957), discussion of pancreas
function tests reported by Popper and Necheles (1959), presentation of lipid
haptensreported by Rapport (1961), survey of serum enzymes in disease reported
by Rose et al. (1961), further information on fibrinolysis reported by Tagnon et al.
(1953) and further information on seminal plasma by Rhodes and Williams-
Ashman (1960).
Anabolic or catabolic enzymes or coenzymes participate in every tumor
according to contemporary cancer concepts whether normal, above normal or
below normal activity levels. The low level may be even the absence of the
enzyme. Apparently, processes to restore when subnormal and destroy or
counteract whenelevated, andpossibly control whennormal, by exogenous means,
are the outline for productive research in cancer enzymology and therapeutic
influence of enzyme activity.434 W. R. DOUGLAS
DISCUSSION OF TRENDS
In the annals of cancer enzymology, there is a continued expansion of rehable
analytic procedures designed for both routine and research requirements which is
certain to accumulate into an adult science ; equivalent, rather than subordinate
to medical biochemistry. When more investigation furnishes data on aR phases
of each enzyme, much should be contributed to understanding cancer. The
metabohe pathways and their affiliated enzymes are yet to be understood, but
progress, even though slow, is being made.
Also, thereismucheffortbeingmadetounderstandenzymereactions,specificity
and behaviour, coupled with more specific definition of same.
In making a closer examination of emphasized trends, it appears, that most,
pronounced is the effort to demonstrateisoenzymes and link them with thespecific
tissues from which they derive. Qualitative and quantitative data have then
the added feature of organ derivation; and cellular differentiation is of tremen-
dous value to any clinician, positively assuring the emergence of enzymology
with new existence, new potential and new importance.
There are scattered trends towards understanding the role of enzymes in
homeostasis, toward the more extensive usage of enzymes as therapeutic agents,
toward human apphcation of certain successful animal studies, toward nutritional
effects on enzymes, toward isolated kinetic studies in pure chemistry unrelated
to disease, toward evaluation of tumor growth and/or efficacy of treatment,
and toward unifying the science, when the contemporary status of enzymes is
considered. It is established at this stage that differences exist among tissues and
organs (Abramoff et al., 1959 ; Bjbrklund andBj6rklund, 1957 ; Bjbrklund et al.,
1958 ; Grace and Lehoczky, 1959 ; Korngold, 1960 ; Witebsky et al., 1956 ;
Zilber, 1959). Most current enzymologists go further and state that aR intra-
cellular enzymes are built into a specific and precise structure and that their
function depends to a large extent on organization (Green and Jdrnefelt, 1959).
Deoxyribonucleic acid synthesis continuing incessantly, although at vastly different rates, provides the only known clue to understanding the real difference
between cancer cells and normal cells. Enzymorphology (Fishman et al., 1961)
must be drawn upon to fortify the chemist. More dissension occurs if the report ofAngeletti et al. (1960), is postulated which claims that tumor proteins resemble
one another closely, and, regardless of the original tissue from which they arise,
tumors would show essentiaRy similar enzyme patterns. However, almost all
agree, the cancer cell, like the normal cell, is exceedingly complex (Weinbouse,
1960)
et al. (1960) reported from their studies witherytbxocyte enzymes that
enzyme defects may be concerned in the shortened survival of red blood cells in
patients withnepbxogenic andneoplasmatic anemia. They studied nine enzymes
on 55 normal subjects and patients with various anemia conditions.
Frei et al. (1961) reported from their studies with leukemic cells and normal
ceRs that the monocytes, derived directly from the reticulo-endothehal system, have glycolytic and proteolytic activity, reducing power and esterase activity markedly greater than that of the neutrophihc polynuclear cells. They stated
that thelymphocytes showed low activeenzymatic functions in comparison to the
neutrophil. The eosinophil was reported in pathologic cases resembhng the
neutrophil inglycolytic activity, but possessing very lowproteolytic capacity and435 ENZYMOLOGY AND CANCER
oxygen consumption. Frei and his associates reported the enz matic behaviour
of the leukemic cell showed diminished proteolytic power in the myeloblast, but
raised glycolysis and occasionally increased esterase activity; in the lympho-
blast, low glycolysis.
Introzzi et al. (1961), claimed that metabolism ofleucocytes from patients with
all forms of leukemia were deficient as shown by a reduction in almost all of the
glycolytic enzymes tested.
Fisher and Fisher (1961) disclosed from theirstudy ofeight enzymes in carcino-
matous tissue by several methods, evidence for proving altered metabolic path-
ways in neoplastic tissue.
Bodansky (1959) reported that some enzymes in the serum, such as alkaline
phosphatase or transaminases, are mixtures of enzymes derived from several
tissues.
Cryogenics and cryohomogenation offer a new tool for the understanding of
multi-enzyme systems and metabolic pathways and provide a new foundation for
the preparation and study of isolated enzyme systems (Klinkhamer and Eichel,
1962).
An uninvestigated possibility is one proposed by Fylling (1961) that fetal
growth and metabolic processes increase enzyme activity in the same way as
rapidly growing neoplastic tissues, this offered as a possible explanation for
enzyme-rich placenta rapidly degenerating at term.
Fishman (1960a) expressed his currentgoal ofinvestigation as being the ability
to identify in the circulation the tissue origin of an enzyme by its
" marks of
identification
" or response to specific inhibitors, and said a degree of success has
been achieved with acid phosphatase by measuring tartrate-sensitive and in-
sensitive moieties and that this has improved clinical accuracy in cancer of the
prostate of the serum ACP determination.
There is some trend toward applying more profoundly chemotherapeutic
efforts on the basis ofenzymatic lesions revealed (Bergel, 1961 ; Weber and Can-
tero, 1960) and the attempts are what may be called enzyme pharmacology,
forming part of a promising line of cancer research (Weber, 1961).
Does the report of Halonen and Konttinen (1962) on effects of strenuous, but
not exhausting, exercise in normal human subjects causing pathological velues
in serum LDH and aldolase activity for temporary periods really have clinical
significance? Certainly clarification of this mechanism is important.
Mason et al. (1961), in a study ofurinary enzyme excretion, have pointed out
that experimental medicine is extremely complicated because of the large number
of interrelated variables which must be considered. Modern computers have the
capacity to handle complicated analysis, store data and results of analyses, plot
curves, and otherwise report results, modify data andreanalyze, until an equation
is reached thatlogically accounts for the variation observed. Analysis ofvariance,
correlation, and multiple regression analysis techniques are ideally suited for such
work, and computer programs are available. Because of the nature of the prob-
lems involved in experimental medicine and the capabilities of modern digital
computers, it would appear that the growth, probably exponential, of computer
use bv physicians in research is assured.
There are many technics in common use currently for characterization of
enzymes and enzyme reactions ; includinor automatic chromatographic analysis
of amino acid mixtures, density gradient ultracentrifugation of macromolecules,
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" finger-printing
" of protein digests, optical rotatory dispersion of proteins,
gas phase chromatography, gel electrophoresis, immuno-electrophoresis, nuclear
magnetic resonance, electron spin resonance, and stop-flow technics for rapid
reaction rates. For studies on enzyme content ofdifferent celltypes, new technics
of mammalian cell culture and of histochemistry are now available. In recent
years there has occurred a culmination of efforts to elucidate patliways of enzy-
matic synthesis of all major types of biological macromolecules, including the
proteins, nuclei acids, steroids, phospholipids, polysaccharides and porphyrins
(Colowick and Kaplan, 1962).
No statement has been made so far inregard to laboratory studies asproof for
a given factor to produce cancer in man (Wynder, 1961) but this is an ultimate
goal for attainment and one in which the involvement of enzymology should be
understood. It is desirable that methods which stand closer to medicine than
chemistry in their structure be increasingly employed in clinical investigations
(Wuhrmann and Wunderly, 1960).
SUMMARY
This review has attempted to cover the wide range of data accumulated in
cancer enzymology with special emphasis on current status and current direction.
Employing the newly approved terminology, all enzymes pertinent to neoplastic
disease in their respective biochemical classification are discussed. Influencing
factors on enzyme activity, carcinogenesis carcino-chemotherapy and research
trends are discussed. Enzymes have been presented with their role in cancer
diagnosis, in cancer therapy, in cancer etiology, in the history of cancer and with
the intention of pointing out the value of enzymology in tumorigenesis. Prime
consideration has been given those correlations which are illustrative of the larger
problems to face in cancer definition.
The International Union ofBiochemistry has the incorporation of its enzyme
commission recommendations in this review. For clarity, whenever possible the
popular name, new trivial name and an assigned abbreviation are employed.
Trends are cited andunexplained enzyme characteristics are noted. Methodo-
logy is surveyed and new analytical technics are presented. An optimistic view
is proffered concerning the development of practical methods for the diagnosis
of cancer and the understanding of mechanisms involved. The trend at present
seems to be delineation of the growth or regression of the tumor, more than the
qualitative or identification testing for cancer, in enzyme determinations.
This review has been as comprehensive, yet concise, as possible. Length and
accentuation of certain enzyme topics herein attest to assessed importance in
cancer enzymology.
I am grateful to a number of colleagues, particularly Professor Mogens Faber
for valuable suggestions and discussions related to this work.
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